ABOUT US

Palladio Biosciences, Inc., a private, venture capital-backed biotech company, was founded in 2015 to develop transformative medicines for orphan diseases of the kidney.

Our first product, lixivaptan, is in Phase 3 development for the treatment of polycystic kidney disease (PKD). PKD is one of the most common, life-threatening genetic diseases. PKD causes numerous fluid-filled cysts to grow in both kidneys. It is a life-limiting, chronic and progressive disease. PKD is the 4th leading cause of kidney failure and carries a significant financial and emotional burden, affecting entire families.

There is no cure for PKD. We are developing lixivaptan to address the continuing unmet needs of patients, as a safe and effective agent to be used chronically to prevent the progression of PKD.

We are supported by a strong, diverse group of venture investors. In September 2020, we completed a $20 million Series B financing led by new investor Samsara BioCapital with participation from new investor Roche Venture Funds and existing investors Medicxi and Osage University Partners. Proceeds from the financing are earmarked to support our Phase 3 ALERT Study and to advance operations. A Series A venture round led by Medicxi in late 2016 allowed us to acquire lixivaptan, establish a team and lay a foundation for clinical development.

Management

Alex Martin

Chief Executive Officer
Mr. Martin is Chief Executive Officer of Palladio Biosciences, a clinical stage biopharmaceutical company developing medicines for orphan diseases of the kidney. He previously served as Chief Executive Officer of Realm Therapeutics (RLM) which was acquired by ESSA Pharma (EPIX) where he now serves as a Director. Mr. Martin was also Chief Operating Officer of Intercept Pharmaceuticals (ICPT), and Chief Finance Officer of BioXell (BXLN) which was acquired by Cosmo Pharmaceuticals (COPN). Mr. Martin began his career at SmithKline Beecham Pharmaceuticals where he held roles of increasing responsibility in marketing and business development and later joined Novartis as Vice President, Global Business Development & Licensing. Mr. Martin is currently Chairman of the Board of Veralox Therapeutics, an active coach and mentor to other senior executives, and a guest lecturer at Wharton and Columbia Business School on biotech, entrepreneurship, and raising capital. Mr. Martin holds a BA from Cornell University and an MBA from Harvard.

Lorenzo Pellegrini, Ph.D.

Founder and Chief Operating Officer
Lorenzo is the Founder and Chief Operating Officer of Palladio Biosciences. Prior to founding Palladio, Lorenzo was a partner at Care Capital, a leading venture capital firm investing in drug development companies. During his twelve-year tenure at Care Capital, Lorenzo co-founded and served on the board of several portfolio companies, including Minerva Neurosciences (NASDAQ: NERV), Biocritica, and Sentinella Pharmaceuticals, among others. He also led the firm’s investments in Elevation Pharmaceuticals (acquired by Sunovion), Anacor Pharmaceuticals (acquired by Pfizer) and Agile Therapeutics (NASDAQ: AGRX). Before joining Care Capital, Lorenzo conducted pre- and post-doctoral research in the Department of Cell Biology at Yale University and at the Max-Planck-Institute for Brain Research in Frankfurt am Main. His original research work was published in leading peer-reviewed scientific journals such as Nature, Cell and Neuron.

Lorenzo received a Laurea in Chemistry, summa cum laude, from the University of Padova, Italy; a Ph.D. in Biochemistry from the Max-Planck-Institute for Brain Research in Frankfurt am Main, Germany; and an M.B.A. with honors from The Wharton School of the University of Pennsylvania.

Marella Thorell

Chief Financial Officer
Marella Thorell is Chief Financial Officer of Palladio Biosciences. Ms. Thorell has more than 25 years of experience in executive financial and operational roles and has successfully led multiple M&A, licensing, and fundraising transactions. Most recently, Ms. Thorell served as CFO/COO and an Executive Director of Realm Therapeutics (Nasdaq: RLM), which was acquired by ESSA Pharma (Nasdaq: EPIX) in July 2019, having previously held a number of other senior positions within Realm. Ms. Thorell was appointed a director of ESSA following the acquisition. Ms. Thorell worked at Campbell Soup Company (NYSE: CPB), in several financial and management roles of increasing responsibility. She was an executive consultant focusing on financial and human capital projects. She began her career and earned her CPA qualification with Ernst & Young, LLP. Ms. Thorell earned a BS in Business from Lehigh University, magna cum laude.

Linda C. Hogan

Chief Business Officer
Linda brings over 30 years of experience in the health care industry, including biotech, venture capital, advisory services, and large pharma. Linda has focused primarily in the areas of product positioning, business strategy and corporate development.

She was most recently an officer and Vice President of Business Development and Strategy for CoLucid Pharmaceuticals, prior to its acquisition by Eli Lilly. As Executive in Residence at Care Capital, a venture capital firm, Linda sourced and evaluated potential investment opportunities, assisting with the startup of several portfolio companies. In 2006, she formed LLH Associates, LLC, a consulting firm which provides business development and strategic transaction support to clients. During her 20 years with Aventis and its predecessor companies, Linda served in various roles of increasing responsibility in diverse functional areas, becoming Vice President, Global Business Development for Aventis.

Prior to joining the pharmaceutical industry, Linda was Assistant Professor of Pharmacy Practice and Director of Drug Information Services for the University of Kansas School of Pharmacy and Kansas University Medical Center. Linda continued as Adjunct Associate Professor Pharmacy Practice and served on the KU School of Pharmacy Advisory Council.

Professional awards include the TWIN (Tribute to Women in Industry) Award and the Donald E. Francke Award from the Drug Information Association. Linda received BS and MS degrees in Pharmacy and Hospital Pharmacy from the University of Kansas and an MBA from Rockhurst College.

Linda is a Life Sciences Council Member of Springboard Enterprises and active with the Licensing Executives Society.

Neil H. Shusterman, MD

Chief Medical Officer
Dr. Neil H. Shusterman is the Chief Medical Officer at Palladio Biosciences. Neil is board certified in internal medicine and nephrology and is a highly experienced drug developer. During his pharmaceutical industry career of over 31 years holding senior senior leadership positions in large, medium, and small companies, Neil contributed to the development or approval of numerous drugs across multiple therapeutic areas, including argatroban injection, Aveed®, Bystolic®, Combunox™, Coreg, Corlopam™, Savella®, Teveten®, Vraylar™, and Xiaflex®. When approved, Coreg was the first new drug approved for heart failure in over 10 years and, in a paradigm shift, established beta blockade as the standard of care for heart failure therapy.

Prior to joining Palladio Biosciences, Neil worked at Endo Pharmaceuticals Inc., where he was the Chief Medical Officer with responsibility for 5 departments – Clinical Development and Operations, Medical Affairs, Drug Safety, Biometrics, and Scientific Communications; at Forest Laboratories, Inc., where he was Senior Vice President of Clinical Development at Forest Research Institute with responsibilities for Phase II – IV clinical development for five therapeutic areas – Cardiovascular, Pulmonary, Gastrointestinal/Metabolism, Psychiatry, and Neurology; and at SmithKline Beecham (subsequently GlaxoSmithKline), where he advanced to Vice President, Cardiovascular Therapeutic Area, North American Medical Affairs, Research and Development with worldwide responsibilities for all Phase II – IV cardiovascular drug development. During his tenure at SmithKline Beecham, Neil led the worldwide pivotal efficacy studies and regulatory filing for Coreg (carvedilol), the first beta-blocker approved for the treatment of chronic heart failure (CHF). That approval led to a paradigm-shift in the treatment of CHF, resulting in reduced morbidity and mortality in this devastating condition. In addition, Neil led several large cardiovascular morbidity and mortality studies that recruited 20,000 patients combined at hundreds of sites on 3 continents.

Before joining the pharmaceutical industry, Neil practiced nephrology at the University of Pennsylvania in Philadelphia, PA where he was Assistant Professor of Medicine and directed a large outpatient dialysis program. Neil has published and presented widely on topics in renal medicine, cardiovascular therapeutics, and drug development. He earned his undergraduate degree from the Pennsylvania State University and his M.D. from Sidney Kimmel Medical College of Thomas Jefferson University in Philadelphia, PA.

Board of Directors

Alex Martin

Chief Executive Officer
Mr. Martin is Chief Executive Officer of Palladio Biosciences, a clinical stage biopharmaceutical company developing medicines for orphan diseases of the kidney. He previously served as Chief Executive Officer of Realm Therapeutics (RLM) which was acquired by ESSA Pharma (EPIX) where he now serves as a Director. Mr. Martin was also Chief Operating Officer of Intercept Pharmaceuticals (ICPT), and Chief Finance Officer of BioXell (BXLN) which was acquired by Cosmo Pharmaceuticals (COPN). Mr. Martin began his career at SmithKline Beecham Pharmaceuticals where he held roles of increasing responsibility in marketing and business development and later joined Novartis as Vice President, Global Business Development & Licensing. Mr. Martin is currently Chairman of the Board of Veralox Therapeutics, an active coach and mentor to other senior executives, and a guest lecturer at Wharton and Columbia Business School on biotech, entrepreneurship, and raising capital. Mr. Martin holds a BA from Cornell University and an MBA from Harvard.

Francesco DeRubertis, Ph.D.

Board of Directors
Francesco is a co-founder and Partner at Medicxi. Prior to Medicxi, Francesco was a Partner at Index Ventures for 19 years, having joined the firm in 1997 to launch its life sciences practice. Under his leadership, the asset-centric approach to life sciences investing was conceived and adopted. Francesco currently serves on the boards of a number of portfolio companies, including Rivus, Orexia and Inexia.

Francesco’s prior investments include CellZome (acquired by GlaxoSmithKline), GenMab (Copenhagen: GEN.CO), GenSight Biologics (Euronext: SIGHT), Micromet (acquired by Amgen), Minerva Neurosciences (NASDAQ:NERV), Molecular Partners (Swiss: MOLN.SW), PanGenetics (acquired by Abbott), Parallele Biosciences (acquired by Affymetrix), Profibrix (acquired by the Medicines Company), and Versartis (NASDAQ:VSAR).

Francesco received a BA in Genetics and Microbology from the University of Pavia and a PhD Molecular Biology from the University of Geneva. He conducted postdoctoral research at the Whitehead Institute at MIT and is a CFA Charterholder. Francesco also serves on the strategic advisory board of the University of Geneva.

Frank Condella

Board of Directors
Frank brings to Palladio Biosciences over 30 years’ experience in senior executive roles in the pharmaceutical industry. In addition to serving on the Board of Trustees of the PKD Foundation for several years, he most recently was President, Chief Executive Officer and a Director of Juniper Pharmaceuticals, Inc. (NASDAQ: JNP), a position he held from 2009 until 2016. Previously, he was Chief Executive Officer of Skyepharma plc, President of European operations at IVAX, Chief Executive Officer of Faulding Pharmaceuticals, Vice President of the specialty care products business at Roche and Vice President and General Manager of the Lederle unit of American Home Products (Pfizer). He currently is Vice Chairman of Vectura Group plc and a Board Director of Juniper Pharmaceuticals. Previously he has served as Chairman of SkyePharma plc, and as an independent Director of Prosonix ltd and Fulcrum Pharma plc.

Mr. Condella earned an MBA from the D’Amore-McKim School of Business and a BS in Pharmacy from Bouvé College of Health Sciences at Northeastern University.

Lorenzo Pellegrini, Ph.D.

Founder and Chief Operating Officer
Lorenzo is the Founder and Chief Operating Officer of Palladio Biosciences. Prior to founding Palladio, Lorenzo was a partner at Care Capital, a leading venture capital firm investing in drug development companies. During his twelve-year tenure at Care Capital, Lorenzo co-founded and served on the board of several portfolio companies, including Minerva Neurosciences (NASDAQ: NERV), Biocritica, and Sentinella Pharmaceuticals, among others. He also led the firm’s investments in Elevation Pharmaceuticals (acquired by Sunovion), Anacor Pharmaceuticals (acquired by Pfizer) and Agile Therapeutics (NASDAQ: AGRX). Before joining Care Capital, Lorenzo conducted pre- and post-doctoral research in the Department of Cell Biology at Yale University and at the Max-Planck-Institute for Brain Research in Frankfurt am Main. His original research work was published in leading peer-reviewed scientific journals such as Nature, Cell and Neuron.

Lorenzo received a Laurea in Chemistry, summa cum laude, from the University of Padova, Italy; a Ph.D. in Biochemistry from the Max-Planck-Institute for Brain Research in Frankfurt am Main, Germany; and an M.B.A. with honors from The Wharton School of the University of Pennsylvania.

Michèle Ollier, MD

Board of Directors
Michèle is a Partner and co-founder of Medicxi, a leading international investment firm focused on life sciences. Prior to co-founding Medicxi, Michèle was a partner at Index Ventures for 10 years, having joined the firm in 2006. During that time she invested and continues to serve on the boards of a number of Index Life Sciences portfolio companies including Epsilon 3 Bio, Minerva Neuroscience (NASDAQ: NERV), LinguaFlex, Gadeta, and Human Antibody Factory. She was also a Director at OncoEthix (sold to Merck Pharmaceuticals) and Aegerion (NASDAQ: AEGR). Prior to joining Index, Michèle was Investment Director at Edmond de Rothschild Investment Partners in Paris for 3 years, where she served on the board of U3 Pharma. Before that, she spent more than 15 years in several development and marketing positions at Sanofi International, BMS, RPR/Gencell/Aventis International and Serono International.

Michèle currently serves on the board of directors of Ipsen Pharmaceuticals (Euronext:IPN) and sits on the investment committees of the accelerator and technology transfer companies of Paris-Saclay and France-Nord.

Michèle completed her medical studies in France at Paris Ouest University.

Sanford (Sandy) Zweifach

Chairman of the Board of Directors
Sandy is the Chairman of the Board of Directors of Palladio Biosciences.

Sandy brings to Palladio over 25 years’ experience in senior executive roles in the life sciences industry, with a focus in corporate partnering, business development, operations, private and public investing, and capital raising. He is the Co-Founder and Chief Executive Officer of Nuvelution Pharma, Inc. Previously, Mr. Zweifach was the Co-founder and CEO of Ascendancy Healthcare, Inc. He has also been a Partner at Reedland Capital Partners, CEO of Pathways Diagnostics, Managing Director and CFO of Bay City Capital, and President and CFO of Epoch Biosciences, which was acquired by Nanogen.

Sandy currently serves as the Chair of IMIDomics SL and Non-Executive Board Member of Compugen, Inc. (NASDAQ: CGEN) and Realm Therapeutics, Inc. He received his BA in Biology from UC San Diego and an MS in Human Physiology from UC Davis.

Adam McNulty

Observer
Adam brings to Palladio Biosciences over 15 years’ pharmaceutical industry experience. Currently leading North American Transactions for Chiesi Group, an Italian multinational, Adam focuses on inorganic growth in support of their rare, specialty care, and respiratory franchises. Prior to his time at Chiesi, he served multiple business development roles within AstraZeneca’s innovative medicines unit, as well as fostering academic spinouts at Harvard Medical School. Mr. McNulty earned an MBA from the D’Amore-McKim School of Business and a BS in Biology from Trinity College.

Carole Nuechterlein

Observer
Carole Nuechterlein has headed the Roche Venture Fund since 2001. Prior to her current position, she worked in the pharmaceutical/biotech industry as an attorney for ten years. She joined Roche from SangStat in Fremont California where she was General Counsel. She currently serves as a director at Aligos Therapeutics, Arch Oncology, BCGT Acquisition Corp, CiVi Biopharma, Entrada Therapeutics, Maculogix, Millendo Therapeutics, Mission Therapeutics, Second Genome and Vivet Therapeutics as well as a board observer on Enliven Therapeutics. She was formerly a director at Allakos and AveXis. She has a BA from Valparaiso University and a JD from University of Michigan. More information on the Roche Venture Fund can be found at www.venturefund.roche.com.

Matt Cohen

Observer
Matt is a Partner at Osage University Partners (OUP) where he has focused on Life Science investments since 2013. He has led OUP’s investments in Arrakis Therapeutics, Biohaven Pharma, Capella Bioscience, Kura Oncology, PMV Pharma, Synthorx, and others. Prior to joining OUP, Matt was a strategy consultant with L.E.K. Consulting serving clients in biopharma and private equity. Matt holds a Ph.D. in Cell and Molecular Biology from The University of Pennsylvania, and a B.S. in Microbiology from The Pennsylvania State University. -- OUP (Osage University Partners) is a venture capital firm focused on investing in startups that are commercializing pioneering university technologies. OUP partners with top research universities to invest in their most innovative startups, and OUP shares its investment profit with its partner institutions. The firm invests in software, hardware, and life science companies at all stages of company development. OUP has partnered with over 100 universities, including 42 of the top 50 U.S. institutions by research expenditures, and has invested in over 100 of their spinouts. OUP is part of a family of investment funds within Osage Partners, which is based in Philadelphia, PA and manages in excess of $800 million. For more information, visit oup.vc.

Srini Akkaraju, MD, PhD

Observer
Srinivas Akkaraju, M.D., Ph.D. is a Founder and Managing General Partner at Samsara BioCapital. Previously, from April 2013 to February 2016, he served as a General Partner of Sofinnova Ventures. From January 2009 until April 2013, he served as Managing Director of New Leaf Venture Partners. Previously, he served as a Managing Director at Panorama Capital, LLC, a private equity firm. Prior to co-founding Panorama Capital, he was with J.P. Morgan Partners, which he joined in 2001 and of which he became a Partner in 2005. From October 1998 to April 2001, he was in Business and Corporate Development at Genentech, Inc. (now a wholly owned member of The Roche Group), a biotechnology company, most recently as Senior Manager. Prior to joining Genentech, Dr. Akkaraju was a graduate student at Stanford University, where he received his M.D. and a Ph.D. in Immunology. He received his undergraduate degrees in Biochemistry and Computer Science from Rice University. Dr. Akkaraju also serves as a director of Intercept Pharmaceuticals and Syros Pharmaceuticals. Previously, Dr. Akkaraju served as a director on the boards of Seattle Genetics, Principia Biopharma, Aravive, Inc., Barrier Therapeutics, Eyetech Pharmaceuticals, ZS Pharma, Synageva Biopharma Corp. and Amarin Corporation.